Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle interventions, produces substantial and sustained weight loss (mean 14.9% at 68 weeks) and improves cardiometabolic risk factors in adults with overweight or obesity.
If you have obesity or overweight with related health issues, once-weekly semaglutide 2.4 mg combined with a modest calorie deficit and regular exercise can lead to significant, sustained weight loss (around 15% on average) and better heart health markers. Start with the lowest dose to minimize stomach upset, and expect side effects like nausea to fade over time.
In STEP 1, in adults with overweight or obesity without T2D receiving semaglutide (n = 1,306) or placebo (n = 655), once-weekly subcutaneous semaglutide plus lifestyle intervention from baseline to week 68 was associated with substantial, sustained, clinically relevant mean weight loss of 14.9% versus 2.4% for placebo... Semaglutide was also associated with greater improvements compared with placebo in cardiometabolic risk factors, including reductions in waist circumference, blood pressure, glycated hemoglobin levels, and lipid levels
Why this rating
Based on multiple phase 3, double-blind, randomized, multinational trials (STEP 1-5) involving nearly 5,000 participants.
Source
Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Anastassia Amaro et al. · Postgraduate Medicine · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →